D. E. Shaw & Co., Inc. - CTI BIOPHARMA CORP ownership

Quarter-by-quarter ownership
D. E. Shaw & Co., Inc. ownership history of CTI BIOPHARMA CORP
ValueSharesWeighting
Q4 2016$9,000
-25.0%
23,260
-28.6%
0.00%
Q3 2016$12,000
+140.0%
32,560
+145.6%
0.00%
Q2 2016$5,000
-73.7%
13,260
-14.4%
0.00%
Q4 2015$19,000
+11.8%
15,492
+35.4%
0.00%
Q3 2015$17,000
-63.8%
11,440
-52.4%
0.00%
Q2 2015$47,000
-34.7%
24,055
-39.6%
0.00%
Q1 2015$72,000
-14.3%
39,849
+12.4%
0.00%
Q4 2014$84,000
-14.3%
35,449
-12.1%
0.00%
Q3 2014$98,00040,3120.00%
Other shareholders
CTI BIOPHARMA CORP shareholders Q3 2023
NameSharesValueWeighting ↓
DAFNA Capital Management LLC 1,425,000$3,363,0002.66%
ACUTA CAPITAL PARTNERS, LLC 1,228,111$2,898,0001.96%
Sio Capital Management, LLC 505,000$1,192,0000.94%
RA Capital Management 2,500,000$5,900,0000.63%
SPHERA FUNDS MANAGEMENT LTD. 750,000$1,770,0000.30%
TFS CAPITAL LLC 1,295,744$3,058,0000.29%
EAGLE ASSET MANAGEMENT INC 12,713,051$30,002,0000.17%
JW Asset Management, LLC 52,271$123,0000.09%
Lombard Odier Asset Management (USA) Corp 501,444$1,183,0000.08%
First Heartland Consultants, Inc. 74,624$176,0000.07%
View complete list of CTI BIOPHARMA CORP shareholders